Eyluxvi (aflibercept biosimilar) / Biolitec - LARVOL DELTA

Alteogen Receives European Commission Approval for Aflibercept Biosimilar, EYLUXVI (ALT-L9) (The Manila Times) - "The EC approval was based on the Phase 3 clinical trials conducted by Alteogen Biologics in 12 countries, including Europe, South Korea and Japan from June 2022 to February 2024."

EMA approval • Diabetic Macular Edema • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025 (European Medicines Agency) - "On 24 July 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Eyluxvi, intended for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV)."

CHMP • Diabetic Macular Edema • Retinal Vein Occlusion • Wet Age-related Macular Degeneration